Cancer Research The Future of Cancer Research: Science and Patient Impact
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 37, 358-364, February 1, 1977]
© 1977 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schultz, R. M.
Right arrow Articles by Chirigos, M. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schultz, R. M.
Right arrow Articles by Chirigos, M. A.

Macrophage Involvement in the Protective Effect of Pyran Copolymer against the Madison Lung Carcinoma (M109)

Richard M. Schultz, Joseph D. Papamatheakis, Josef Luetzeler1, Phillip Ruiz and Michael A. Chirigos

Viral Biology Branch, National Cancer Institute, NIH, Bethesda, Maryland 20014

Pyran copolymer (NSC 46015) therapy markedly enhanced host resistance to a murine lung carcinoma (M109) implanted s.c. Multiple dose schedules were not significantly better than single doses at increasing lifespan. Although tumor necrosis was much more extensive in the lesions of pyran-treated mice, pyran copolymer was not directly toxic to M109 cells in vitro. A comparative histopathological study revealed an intense histiocytic reaction in the connective tissue surrounding the primary tumor in mice receiving pyran as compared to 0.9% NaCl solutiontreated controls. Macrophages were often associated with necrobiotic tumor cells. Morphologically activated macrophages were recovered from pyran-treated animals which potently inhibited DNA synthesis of M109 tumor cells in vitro. This response peaked 6 days after drug treatment and was to a large extent specific for neoplastic cells. Our results from both in vivo and in vitro studies support the concept that pyran enhances host resistance to neoplasia by mobilization and activation of the reticuloendothelial elements of the host's defense.

1 Visiting scientist from the Immunopathology Department, University of Cologne, West Germany.

Received 8/17/76. Accepted 10/25/76.




This article has been cited by other articles:


Home page
Journal of Bioactive and Compatible PolymersHome page
T. Sawa, Y. Okumura, J. Sunamoro, J. L. Ding, and R. M. Ottenbrite
Enhanced Growth of Cultured Fibroblasts by a Synthetic Polyanionic Polymer
Journal of Bioactive and Compatible Polymers, January 1, 1996; 11(1): 17 - 27.
[Abstract]


Home page
Journal of Bioactive and Compatible PolymersHome page
L. Seymour
Review : Synthetic Polymers with Intrinsic Anticancer Activity
Journal of Bioactive and Compatible Polymers, January 1, 1991; 6(2): 178 - 216.
[PDF]


Home page
ScienceHome page
R. Schultz, J. Papamatheakis, and M. Chirigos
Interferon: an inducer of macrophage activation by polyanions
Science, August 12, 1977; 197(4304): 674 - 676.
[Abstract] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1977 by the American Association for Cancer Research.